Welcome to our dedicated page for Illumina SEC filings (Ticker: ILMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Illumina Inc (ILMN) SEC filings, offering a view into the company’s regulatory disclosures, financial reporting, and material corporate events. Illumina’s common stock is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Stock Market LLC under the symbol ILMN, as noted in multiple Form 8-K filings.
Investors and analysts can use this filings feed to review Illumina’s current and historical reports, including Forms 10-K and 10-Q referenced in company press releases, as well as Form 8-K filings that detail significant events. Recent 8-Ks describe preliminary unaudited financial results, quarterly earnings announcements, and capital markets transactions such as the issuance of 4.750% notes due 2030 under an existing indenture, along with expected uses of proceeds for general corporate purposes and potential acquisitions.
Filings also outline material agreements and strategic transactions. For example, an 8-K dated June 22, 2025 describes a Stock Purchase Agreement under which Illumina will acquire Standard BioTools’ aptamer-based and functional proteomics business, including SomaLogic, subject to regulatory approvals and customary closing conditions. These documents provide details on purchase price, milestone payments, regulatory conditions, and termination provisions.
On Stock Titan, SEC filings for Illumina are paired with AI-powered summaries designed to highlight key elements of each document. Users can quickly identify important information in annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K), as well as access data on registered securities and capital structure. Real-time updates from EDGAR ensure that new filings, including any future debt offerings, material agreements, or other reportable events, appear promptly, while AI-generated overviews help readers navigate complex regulatory language more efficiently.
Illumina, Inc. (ILMN) reported an insider transaction by its VP, Chief Accounting Officer.
On 11/05/2025, 206 shares of common stock were disposed of at $122.44 under transaction code F. After this transaction, the reporting person beneficially owns 13,486 shares, held directly.
Illumina (ILMN) insider transaction: The company’s SVP, Chief People Officer reported a Form 4 transaction on 11/05/2025. The filing shows a Code F entry for Common Stock with 296 shares disposed at $122.44 per share. Following this transaction, the officer beneficially owns 19,391 shares, held directly.
Illumina, Inc. (ILMN) insider transaction reported. An officer (Chief of Global Operations) filed a Form 4 for a transaction on 11/05/2025. The filing reports the disposition of 599 shares of common stock at $122.44 per share with transaction code F.
Following the reported transaction, the insider beneficially owned 22,476 shares, held directly. The filing was made by one reporting person.
Illumina, Inc. (ILMN) filed a Form 4 reporting an insider transaction by SVP & Chief Technology Officer Steven Barnard. The filing lists a 11/05/2025 transaction in which 515 shares of common stock were disposed of, coded “F,” at a price of $122.44 per share. After this transaction, Barnard directly beneficially owned 33,031 shares.
Illumina (ILMN) reported an insider purchase on Form 4. Director Scott Gottlieb bought 500 shares of common stock on 11/03/2025 at $122.13 per share, raising his direct holdings to 12,523 shares. The filing indicates it was submitted by an authorized signatory on 11/05/2025.
Illumina, Inc. reported Q3 2025 results with total revenue of $1,084 million, essentially flat year over year ($1,080 million). Product revenue was $927 million, led by sequencing consumables at $747 million, while service and other revenue was $157 million. Net income was $150 million, or $0.98 diluted EPS. Income from operations was $227 million, reflecting higher gross margin versus last year’s mix and the absence of prior-year settlement credits.
Year to date, revenue was $3,184 million and net income reached $516 million. Cash from operations was $758 million, supporting $706 million of share repurchases (7.45 million shares) under a $1.5 billion authorization. Cash and cash equivalents were $1,050 million, short‑term investments $228 million, and term debt totaled $1,992 million (with $998 million current). The company disclosed $747 million in remaining performance obligations (77% expected within 12 months) and noted ongoing headwinds in Greater China. Illumina agreed to acquire SomaLogic and certain assets from Standard BioTools for
Jacob Thaysen, who is listed as Chief Executive Officer and a Director of Illumina, Inc. (ILMN), reported a sale of company stock on 10/05/2025. The filing shows 1,301 shares were disposed of at a price of $101.02 per share. After the transaction the reporting person beneficially owned 82,089 shares, held in a direct ownership form. The Form 4 was signed on 10/07/2025.
Scott B. Ullem, a director of Illumina, Inc. (ILMN), reported on Form 4 that on 09/30/2025 he acquired 252 shares of Illumina common stock issued in lieu of cash retainer fees at an implied price of $99.1666 per share. Following the transaction he beneficially owns 8,389 shares, held directly. The filing states Mr. Ullem elected to receive 100% of his 2025 board and committee cash retainer fees in Illumina stock, with share counts determined using the quarter’s volume-weighted average closing price. The form is signed on 10/02/2025.
Illumina insider Steven Barnard, SVP and Chief Technology Officer, reported a sale of 287 shares of Common Stock on 09/05/2025 at a reported price of $98.93 per share, leaving him with 33,546 shares beneficially owned after the transaction. The Form 4 was signed by Robert Maynes on behalf of Mr. Barnard on 09/09/2025. The filing lists no derivative transactions.
FAQ
What is the current stock price of Illumina (ILMN)?
What is the market cap of Illumina (ILMN)?
